Immunome, Inc.
IMNMHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Immunome, Inc. (IMNM) is listed under Biotechnology. Valued at $2.53B, IMNM is a mid-cap name in its sector. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Market Cap
$2.53B
Beta
2.07
P/E (TTM)
—
P/E (Fwd)
-10.53
EPS (TTM)
$-2.39
EPS (Fwd)
$-2.12
ROE
-50.1%
ROA
-29.7%
Cash
$582.7M
Total Debt
$3.7M
Free CF
-$139.3M
52W Change
111.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $582.7M in cash comfortably exceeding the $3.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$139.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -50.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, IMNM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immunome, Inc.'s trajectory.